The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone: A Randomized, Double-Blind, Placebo-Controlled Trial
Abstract
BACKGROUND: Corticosteroids remain the cornerstone of therapy for giant-cell arteritis, but relapse during dose tapering and corticosteroid-related adverse events often complicate management of this condition. Although several approaches, including combined therapy with cytotoxic agents, have been suggested to overcome these problems, no study has clearly shown benefits of alternate treatments. OBJECTIVE: To analyze the safety and efficacy of combined therapy with corticosteroids and methotrexate in giant-cell arteritis. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: University-based clinic. PATIENTS: 42 patients with new-onset giant-cell arteritis according to biopsy. INTERVENTION: High initial doses of corticosteroid were given; the dose was then tapered quickly until therapy was completely withdrawn. Methotrexate or placebo was given weekly from the start of corticosteroid therapy for 24 months. MEASUREMENTS: Number of relapses, cumulative dose of corticosteroid, and number of adverse events were assessed on completion of follow-up. RESULTS: Compared with combined prednisone and placebo therapy, treatment with prednisone and methotrexate reduced the proportion of patients who experienced at least one relapse (45% vs. 84.2%; P = 0.02) and the proportion of patients who experienced multiple relapses (P = 0.004). The mean cumulative dose of prednisone was 4187 +/- 1529 mg in the methotrexate group and 5489.5 +/- 1396 mg in the placebo group (mean difference, 1302 mg [95% CI, 350 to 2253 mg]; P = 0.009). Overall, the rate and severity of adverse events were similar between groups. Treatment was discontinued in 3 patients in the methotrexate group who experienced definite drug-related adverse events. In sensitivity analysis that included patients lost to follow-up, differences between groups in number of relapses and cumulative dose of prednisone were significant. CONCLUSIONS: Treatment with methotrexate plus corticosteroid is a safe alternative to corticosteroid therapy alone in patients with giant-cell arteritis and is more effective in controlling disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Temporal Arteritis: A 25-Year Epidemiologic, Clinical, and Pathologic Study
HUSTON, K. A., HUNDER, G. G., LIE, J. T., KENNEDY, R. H., & ELVEBACK, L. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-2-162 · Cited by 547
Morgan, S. L., Baggott, J. E., Vaughn, W. H., Austin, J. S., Veitch, T. A., Lee, J. Y., Koopman, W. J., Krumdieck, C. L., & Alarcon, G. S. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-11-199412010-00002 · Cited by 360
Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
De Silva, M., & Hazleman, B. L. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.2.136 · Cited by 360
Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica
Gabriel, S. E., Sunku, J., Salvarani, C., O'Fallon, W. M., & Hunder, G. G. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401022 · Cited by 239
van der Veen, M. J., Dinant, H. J., van Booma-Frankfort, C., van Albada-Kuipers, G. A., & Bijlsma, J. W. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.4.218 · Cited by 212
Guidelines for monitoring drug therapy in rheumatoid arthritis
American College of Rheumatology AD Hoc Committee on Clinical Guidelines (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390503 · Cited by 193
Simms, R. W., Kwoh, C. K., Anderson, L. G., Erlandson, D. M., Greene, J. M., Kelleher, M. E., O’Dell, J. R., Partridge, A. J., Roberts, W. N., Robbins, M. L., et al. (1996) · PubMed · Cited by 182
Delecoeuillerie, G., Joly, P., Cohen de Lara, A., & Paolaggi, J. B. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.9.733 · Cited by 181
Kyle, V., & Hazleman, B. L. (1989) · Annals of the Rheumatic Diseases · doi:10.1136/ard.48.8.658 · Cited by 151
Kyle, V., & Hazleman, B. L. (1989) · Annals of the Rheumatic Diseases · doi:10.1136/ard.48.8.662 · Cited by 140
Cited by
Isselbacher, E. M., Preventza, O., Hamilton Black, J., Augoustides, J. G., Beck, A. W., Bolen, M. A., Braverman, A. C., Bray, B. E., Brown-Zimmerman, M. M., Chen, E. P., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001106 · Cited by 2,082
Polymyalgia Rheumatica and Giant-Cell Arteritis
Salvarani, C., Cantini, F., Boiardi, L., & Hunder, G. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011913 · Cited by 1,352
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215672 · Cited by 1,200
Polymyalgia rheumatica and giant-cell arteritis
Salvarani, C., Cantini, F., & Hunder, G. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61077-6 · Cited by 767
Polymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 687
Metadata
- Authors
- Jover, J. A., Hernández-García, C., Morado, I. C., Vargas, E., Bañares, A., & Fernández-Gutiérrez, B.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2001-01-16
- Volume
- 134
- Issue
- 2
- Pages
- 106-114
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2004589503
- Cited by
- 518
- References
- 14
- FWCI
- 17.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone: A Randomized, Double-Blind, Placebo-Controlled Trial. https://app.cochat.ai/papers/10.7326/0003-4819-134-2-200101160-00010
- The paper
- Jover, J. A., Hernández-García, C., Morado, I. C., Vargas, E., Bañares, A., & Fernández-Gutiérrez, B. (2001). Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone: A Randomized, Double-Blind, Placebo-Controlled Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-134-2-200101160-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.